(Q46990084)

27 December 2017

title

Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. (English)

1 reference

27 December 2017

1 reference

Daisuke Yamamoto

1

1 reference

27 December 2017

Shinji Takai

2

1 reference

27 December 2017

Denan Jin

3

1 reference

27 December 2017

Sachiko Inagaki

4

1 reference

27 December 2017

Kazuhiko Tanaka

5

1 reference

27 December 2017

Mizuo Miyazaki

6

1 reference

27 December 2017

publication date

16 August 2007

1 reference

27 December 2017

Journal of Molecular and Cellular Cardiology

published in

1 reference

27 December 2017

volume

43

1 reference

27 December 2017

issue

6

1 reference

27 December 2017

page(s)

670-676

1 reference

27 December 2017

Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Angiotensin receptor blockers and myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Angiotensin receptor blockers do not increase risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Crystal structure of the human angiotensin-converting enzyme-lisinopril complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Molecular dynamics with coupling to an external bath

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Impact of chymase inhibitor on cardiac function and survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2007.08.002

10.1016/J.YJMCC.2007.08.002

7 January 2021

Identifiers

DOI

1 reference

27 December 2017

PubMed ID

17884087

1 reference

27 December 2017